Headache severity was recorded using a four-grade scale (no pain, mild pain, moderate pain, severe pain) at six time points, baseline (time of taking study drug) and at 0.5, 1, 1.5, 2, and 24 h thereafter.
Migraine symptoms were measured with the Migraine Symptom Severity Scale (MSSS), a composite index that incorporates information about 7 headache features (unilateral pain, pulsatile pain, moderate or severe pain intensity, routine activities worsen pain, nausea, photophobia, phonophobia).
To be included, patients had to describe all the pain features of TTH: bilateral location, pressing and tightening pain, moderate intensity (≤6 on a 10-points numerical pain rate scale, NPRS) and no aggravation of pain during physical activity.
She was pain-free for further 2 years, then she began suffering from a new occipital bilateral pressing pain, moderate, sometimes with nausea, presenting exclusively during sleep and causing awakening.
Supportive measures include antibiotics to prevent infections in weakened muscles, analgesics for pain, moderate exercise and a nutritious diet.
Each of the three conditions described above was performed under periods of no pain, moderate pain, and high pain.
Two independent variables were entered into the model: heat pain level (no pain, moderate pain, and high pain), and condition (acquaintance, partner, and distraction).
Table 1 presents pain ratings for the three tasks (acquaintance picture baseline, distraction control, and partner picture task), and three temperature levels (no pain, moderate-pain, and high-pain).
Patients' replies included categorization of pain experienced as "no pain", "slight pain", "moderate pain" or "severe pain".
Outcome measures included a subjective pain scale (no pain, mild pain, moderate pain, severe pain, excrutiating pain) at baseline and after four weeks of treatment.
